poseida.com (PSTX): Net earnings per share growth forecast for next year

The implementation of green chemistry principles and sustainable waste disposal correlate with an upward trend, where the projected growth in earnings per share for the next fiscal year reflects inflated market expectations for Poseida Therapeutics (PSTX). The value of -105.00 serves as the current parameter value. Poseida Therapeutics (PSTX) relies on outsourcing vector production while retaining proprietary patents, and its unique CAR-T editing platform and support from pharma behemoths strengthen its competitive moat.

Poseida Corp (PSTX): Net earnings per share growth forecast for next year from 07/04/2022 to 01/18/2025

Summary analytical data breakdowns for Poseida Therapeutics, Inc. (PSTX)

- share price and consensus valuation forecast:

Stock Price Poseida Therapeutics Inc|PSTX - Average Forecast Price

- stock exchange capitalization data:

Market Value Poseida Therapeutics Inc|PSTX - Total Company Value

- company book value details:

Net Assets per Single Share Poseida Therapeutics|PSTX - Company Book Value|Market Cap to Net Assets Ratio poseida.com|PSTX - Aggregate Asset Value

- debt and solvency information:

- net income and valuation ratios data:

PSTX - Final Profit|Future Profit Poseida Therapeutics|PSTX - Market Price to Net Income Ratio|Forward P/E Multiple Poseida Therapeutics, Inc.|PSTX - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Poseida Therapeutics|PSTX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Poseida Therapeutics|PSTX - Earnings per share for the trailing year|Quarterly EPS earnings growth poseida.com|PSTX - Earnings growth in current year|Net earnings per share growth forecast for next year Poseida Therapeutics

- company sales and revenue statistics:

PSTX - Company Annual Revenue|Company Future Sales Volume Poseida Therapeutics Inc|PSTX - Price to Sales|Price-to-Projected Revenue Ratio Poseida Therapeutics, Inc.

Fundamental company analysis:PSTX, Poseida Therapeutics, Inc.

For Poseida Therapeutics (PSTX), the earnings per share growth model for next year reflects market expectations for the monetization of gene technologies, accounting for safety risks and patent disputes. This indicator measures the weighted average analyst forecast for EPS dynamics, where excessive optimism signals valuation overheating, increasing the likelihood of a sharp correction upon any negative clinical data.

Competing companies